



## Exelixis Announces Webcasts of Upcoming November Investor Conference Presentations

November 21, 2017

-- Presentations to be webcast on [www.exelixis.com](http://www.exelixis.com) --

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 21, 2017-- Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will provide an overview of the company at the following two investor conferences in the coming weeks:

- Piper Jaffray 29th Annual Healthcare Conference: Exelixis' presentation is scheduled for 11:00 AM EST / 8:00 AM PST on Tuesday, November 28, 2017 in New York, NY.
- Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference: Exelixis' presentation is scheduled for 12:05 PM EST / 9:05 AM PST on Wednesday, November 29, 2017 in Boston, MA.

To access the webcast link, log onto [www.exelixis.com](http://www.exelixis.com) and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company's website at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to listen to the webcast. A replay will also be available at the same location for 14 days.

### About Exelixis

Founded in 1994, Exelixis, Inc. (NASDAQ: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model genetic systems, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need. We discovered our lead compounds, cabozantinib and cobimetinib, and advanced them into clinical development before entering into partnerships with leading biopharmaceutical companies in our efforts to bring them to patients globally. We are steadfast in our commitment to prudently reinvest in our business to maximize the potential of our pipeline. We intend to supplement our existing therapeutic assets with targeted business development activities and internal drug discovery – all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. Exelixis recently earned a spot on Deloitte's Technology Fast 500 list, a yearly award program honoring the 500 fastest-growing companies over the past four years. For more information about Exelixis, please visit [www.exelixis.com](http://www.exelixis.com) or follow @ExelixisInc on Twitter.



View source version on businesswire.com: <http://www.businesswire.com/news/home/20171121006080/en/>

Source: Exelixis, Inc.

### Investors Contact:

*Exelixis, Inc.*

*Susan Hubbard, 650-837-8194*

*EVP, Public Affairs and Investor Relations*

[shubbard@exelixis.com](mailto:shubbard@exelixis.com)

or

### Media Contact:

*For Exelixis, Inc.*

*Hal Mackins, 415-994-0040*

[hal@torchcommunications.com](mailto:hal@torchcommunications.com)